| Basics |
Alkermes plc Ordinary Shares
Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.
|
| IPO Date: |
August 1, 1991 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$4.71B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.49 | 1.87%
|
| Avg Daily Range (30 D): |
$0.63 | 2.06%
|
| Avg Daily Range (90 D): |
$0.54 | 1.82%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.08M |
| Avg Daily Volume (30 D): |
2.04M |
| Avg Daily Volume (90 D): |
1.78M |
| Trade Size |
| Avg Trade Size (Sh.): |
116 |
| Avg Trade Size (Sh.) (30 D): |
66 |
| Avg Trade Size (Sh.) (90 D): |
65 |
| Institutional Trades |
| Total Inst.Trades: |
13,879 |
| Avg Inst. Trade: |
$2.54M |
| Avg Inst. Trade (30 D): |
$3.25M |
| Avg Inst. Trade (90 D): |
$3.19M |
| Avg Inst. Trade Volume: |
.09M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$5.29M |
| Avg Closing Trade (30 D): |
$9.26M |
| Avg Closing Trade (90 D): |
$9.11M |
| Avg Closing Volume: |
179.23K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$2.07
|
$.5
|
$.53
|
|
Diluted EPS
|
$2.01
|
$.49
|
$.52
|
|
Revenue
|
$ 1.52B
|
$ 394.19M
|
$ 390.66M
|
|
Gross Profit
|
$ 1.31B
|
$ 342.59M
|
$ 341.2M
|
|
Net Income / Loss
|
$ 338.83M
|
$ 82.76M
|
$ 87.1M
|
|
Operating Income / Loss
|
$ 358.54M
|
$ 89.08M
|
$ 92.98M
|
|
Cost of Revenue
|
$ 212.36M
|
$ 51.59M
|
$ 49.46M
|
|
Net Cash Flow
|
$ 220.16M
|
$ 95.25M
|
$ 121.39M
|
|
PE Ratio
|
13.96
|
|
|
|
|
|
